Literature DB >> 50159

The analgesic properties of delta-9-tetrahydrocannabinol and codeine.

R Noyes, S F Brunk, D A Avery, A C Canter.   

Abstract

The administration of single oral doses of delta-9-tetrahydrocannabinol (THC) to patients with cancer pain demonstrated a mild analgesic effect. At a dose of 20 mg, however, THC induced side effects that would prohibit its therapeutic use including somnolence, dizziness, ataxia, and blurred vision. Alarming adverse reactions were also observed at this dose. THC, 10 mg, was well tolerated and, despite its sedative effect, may analgesic potential.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 50159      PMCID: PMC8332526          DOI: 10.1002/cpt197518184

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  68 in total

Review 1.  Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review.

Authors:  F A Campbell; M R Tramèr; D Carroll; D J Reynolds; R A Moore; H J McQuay
Journal:  BMJ       Date:  2001-07-07

Review 2.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

3.  [Endogenous cannabinoid system. Effect on neuronal plasticity and pain memory].

Authors:  S C Azad; V Huge; P Schöps; C Hilf; A Beyer; H-U Dodt; G Rammes; W Zieglgänsberger
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

4.  Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia.

Authors:  Darryl T Hamamoto; Subhalakshmi Giridharagopalan; Donald A Simone
Journal:  Eur J Pharmacol       Date:  2006-12-09       Impact factor: 4.432

Review 5.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Effects of oral Δ9-tetrahydrocannabinol on the cerebral processing of olfactory input in healthy non-addicted subjects.

Authors:  Carmen Walter; Bruno G Oertel; Lisa Felden; Ulrike Nöth; Johannes Vermehren; Ralf Deichmann; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2017-09-02       Impact factor: 2.953

Review 7.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Effects of 20 mg oral Δ(9) -tetrahydrocannabinol on the olfactory function of healthy volunteers.

Authors:  Carmen Walter; Bruno G Oertel; Dagmar Ludyga; Alfred Ultsch; Thomas Hummel; Jörn Lötsch
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

9.  Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.

Authors:  Kristina B Svendsen; Troels S Jensen; Flemming W Bach
Journal:  BMJ       Date:  2004-07-16

Review 10.  A Comprehensive Review of Cannabis in Patients with Cancer: Availability in the USA, General Efficacy, and Safety.

Authors:  Grant Steele; Tom Arneson; Dylan Zylla
Journal:  Curr Oncol Rep       Date:  2019-02-01       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.